All News
From Domains to Decisions: Personalizing PsA Care with Data
At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary stage to reframe how we think about treating psoriatic arthritis. The message was clear: in 2025, PsA treatment is no longer about following a linear algorithm; it’s about understanding the unique constellation of domains, comorbidities, and patient factors that shape each clinical decision.
Read Article
Secukinumab Use in Refractory Giant Cell Arteritis
In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/HkMT9QEMg8
Dr. John Cush RheumNow ( View Tweet)
#EULAR2025 Abstr#OP0041 FcRn-inhibition is showing consistency in #Sjogren. Last year it was Nipocalimab. This proof-of-concept study showed efgartigimod met its primary endpoint, the CRESS response. No difference in ESSPRI. Phase 3 UNITY is underway @RheumNow https://t.co/jw1i4FqkIh
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2025 Abstr#OP0035 SGLT2-i and GLP-1 agonist are increasingly used to treat diabetes. Population based study in Canada showed no significant difference in risk of developing an autoimmune rheumatic disease with GLP-1-RA or SGLT2i relative to DPP4i treatment @RheumNow https://t.co/CvPcOqehtl
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2025 Abstr#OP0202 Phase 1/2 of Resel-cel, a 4-1BB-containing human CD19-CAR T cell (weight-based 1 x infusion) reported efficacy in 8 patients (#SLE and LN) at WK28. 2 x Grade 1 CRS & 1 x Grade 4 ICANS. 1 x HLH, not attributed to SLE flare. Need longterm data @RheumNow https://t.co/COCKlqw687
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#Enpatoran a #TLRi in Phase2 #SLE #RCT
-previous data + small #cutaneous #lupus study
various doses &PBO approx 25/group
Interesting data - seems to ⬇️#IFN
+ endpoints
👀 for more to come! Safe so far
#EULAR2025 @RheumNow @eular_org LateBreaking I https://t.co/OtgiasBerX
Links:
Janet Pope Janetbirdope ( View Tweet)
Key summary slide of research in the use of CD19 CAR T cells in rheumatology indications
Dinesh Khanna @RheumNow #EULAR2025 https://t.co/CoFHqaE1L1
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Which CAR-based strategies would you consider to treat severe refractory #SLE based on data presented at #EULAR2025? @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
URAT1 inhibitors look like the way to go in Gout!
Presented in multiple abstracts at #EULAR2025
Pozdeutinurad Ph2 long term safety data chronic gouty arthritis + tophi OP0300
Ph3 RCT of Ruzinurad in hyperuricemia/primary gout OP0302
Ph 2b RCT of SAP-001 Refractory Gout +/-
Aurelie Najm AurelieRheumo ( View Tweet)
Deucravacitinib, the first oral TYK2 inhibitor, delivers in PsA:
✅ ACR20: 54% vs 34% (placebo)
✅ Skin, joints, fatigue, QoL
📉 Post hoc: less radiographic progression
No new safety signals at W16.
LB0001 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
from Rituximab to BiTES to CAR T, always looking for deeper B cell depletion
Safety data from CC312 CD19/CD3/CD28, a triple engager in refractory moderate-to-severe SLE
So far so good but how far do we need to go?
#EULAR2025 @RheumNow LB0007
Aurelie Najm AurelieRheumo ( View Tweet)
🌳#WILLOW: TLR7/8 inhibition with enpatoran led to greater BICLA response, IFN signature reduction & skin improvement (CLASI-50/70) in active SLE vs placebo at 24wks. Most benefit seen in pts with high IFN-GS or GC use. Good tolerability.
@RheumNow #EULAR2025 #LB0004
Mrinalini Dey DrMiniDey ( View Tweet)
Nerandomilast: the new & improved nintedanib.
Does it work for our rheum pts?
Autoimmune subgroup of FIBRONEER-ILD (NEJM last month)
- mortality benefit vs placebo (this is new)
- well tolerated (minimal increase in diarrhoea vs placebo)
One to watch
#EULAR2025 LB0003 @RheumNow https://t.co/u8fIy7kkKW
Links:
David Liew drdavidliew ( View Tweet)
FIBRONEER-ILD Ph3 PD4B inhibitor Nerandomilast
1100+ pts, 320+ w/ SARD-ILD wk52
FVC relative reduction of decline 9 mg bid 43% 18 mg bid 39% vs. PBO
HR 0.56 time to first acute exacerbation of ILD, hospitalisation for resp cause or death in higher dose group
11% https://t.co/CeXWB2GlOe
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2025 Abstr#LB0004 Phase 2 RCT of first-in-class, Enpatoran, TLR7/8-i in active #SLE despite SOC (Cohort B) reported nominal improvement in BICLA but no dose-dependent response. Greater effects seen on active CLE, high IFN-GS or high dose GC. No major safety signal @RheumNow https://t.co/aX4ier0rAy
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Enpatoran (TLR7/8 inhibitor) in SLE & CLE
- helps skin, others?
- suppresses interferon
lowest dose was highest response though (upsetting primary endpoint)
Promising, watch for the ph3
No photos allowed, but official slides:
https://t.co/1yX6XrYvKH
#EULAR2025 LB0004 @RheumNow
David Liew drdavidliew ( View Tweet)
💉Early results from a dose-escalation trial of novel CD19xCD3xCD28 trispecific antibody (CC312) in refractory #SLE show no ICANS or ≥G2 CRS, rapid B cell depletion & 100% SRI-4 response (n=5).
@RheumNow #EULAR2025 #LB0007 #CART
Mrinalini Dey DrMiniDey ( View Tweet)
🦵🏻SAP-001, a novel uricosuric targeting a non-URAT1 renal transporter, lowered sUA <6 mg/dL in up to 79% of patients with refractory #gout on b/g xanthine oxidase inhibitor. >50% on 60 mg/day reached sUA <3 mg/dL.
💊Potential new oral ULT option.
@RheumNow #EULAR2025 #LB0008 https://t.co/dfY1V5sHSh
Mrinalini Dey DrMiniDey ( View Tweet)
Results from open label
extension of BE-OPTIMAL:
-Bimekizumab in bDMARD naïve pts showed sustained efficacy after 1y until 3y.
-No significant major tolerability issues or major SE.
abstract #POS1294
#EULAR2025
@RheumNow https://t.co/VAEiciCR1z
Adela Castro AdelaCastro222 ( View Tweet)
#EULAR2025 Abstr#LB0007 Two’s Company, Three’s a Crowd! In 5 #SLE pts treated with CC312, a novel CD19/CD3/CD28 tri-specific ab in dose escalation showed rapid & B-cell depletion & all achieved SRI-4. No =>G2 CRS or ICANS. USP: off-the-shelf & overcome T-cell exhaustion @RheumNow https://t.co/6DZRj09JEQ
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
